Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377464 | 0.97 | RXFP1 (0.36) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL13377457 | 0.76 | — | — | |
| SCHEMBL13377320 | 0.76 | RXFP1 (0.36) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL13377365 | 0.72 | RXFP1 (0.40) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL21957120 | 0.69 | AR (0.41) | RXFP1 | |
| SCHEMBL21956885 | 0.67 | RXFP1 (0.35) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL19272328 | 0.65 | RAB9A (0.40) | RXFP1LMNANPSR1KDM4E | |
| SCHEMBL17085625 | 0.65 | KDM4E (0.35) | RXFP1LMNANPSR1KDM4E | |
| SCHEMBL22017353 | 0.65 | POLB (0.35) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL22016172 | 0.65 | RXFP1 (0.33) | RXFP1LMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | UQCRB, CCNB3, CCNB1 | RXFP1 797/4885LMNA 2155/4885TSHR 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.